Darolutamide significantly delays the metastasis of de-resistant prostate cancer

new study, published in new England Journal of Medicine, showed that treating non-metastatic despotical prostate cancer with drarolutamide significantly extended patients' non-metastatic survival compared to placebos, and was presented on the same day at the Annual Meeting of the American Society of Clinical Oncology in San Francisco.
Dr. Karim Fizazi and colleagues from the University of Paris-11 randomly divided patients with non-metastatic desopathic prostate cancer into two groups (2:1), receiving drarolutamide (955 people twice a day, 600 mg each) and placebo (554 people) while maintaining androgen blocking therapy.
researchers found that in the planned primary endpoint analysis, patients in the darolutamide group had a medium non-transferable survival of 40.4 months, compared with 18.4 months in the control group (the transfer or death hazard ratio in the darolutamide group was 0.4). In terms of secondary endpoints, darolutamide also brings clinical benefits to patients, such as total survival rate, time of pain progress, time of cytotoxic chemotherapy, and time of symptomatic skeletal events.
two groups of patients had a similar probability of having a series ≥3, frequency≥5% of side effects, and the proportion of patients in both groups who stopped the experiment due to side effects was similar, at 8.9% and 8.7%, respectively.
59 percent lower risk of metastasis or death for any reason, and all sub-groups of patients benefited, including those at lower risk. The author wrote.
by Bayer Medical and Orion Pharma, the makers of Darolutamide. (Bio Valley)